Details of the Drug

General Information of Drug (ID: DMA7PEW)

Drug Name
Verapamil
Synonyms
Arpamyl; Calan; Calcan; Cordilox; Dexverapamil; Dilacoran; Drosteakard; Iproveratril; Isoptimo; Isoptin; Isotopin; Vasolan; Veracim; Verapamilo; Verapamilum; Veraptin; Verexamil; Bosoptin (TN); Calan (TN); D-365; Isoptin (TN); Verapamilo [INN-Spanish]; Verapamilum [INN-Latin]; Verelan (TN); CP-16533-1; Covera-HS (TN); Verapamil (USAN/INN); Verapamil [USAN:BAN:INN]; Verapamil [USAN:INN:BAN]; Alpha-((N-Methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-Isopropyl-alpha-((N-methyl-N-homoveratryl)-gamma-aminopropyl)-3,4-dimethoxyphenylacetonitrile; Alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)-methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile; (+-)-Verapamil; (+/-)-VERAPAMIL; (1)-3-(3,4-Dimethoxyphenyl)-6-((5,6-dimethoxyphenethyl)methylamino)hexane-3-carbonitrile; 2-(3,4-Dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-(1-methylethyl) pentanenitrile; 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile; 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile; 5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile; Verapamil (Na-Ca chanel blocker)
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 454.6
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 13
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 18 mL/min/kg [4]
Elimination
1.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.8 hours [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.093% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.7 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.75 mg/mL [3]
Chemical Identifiers
Formula
C27H38N2O4
IUPAC Name
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile
Canonical SMILES
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
InChIKey
SGTNSNPWRIOYBX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2520
ChEBI ID
CHEBI:77733
CAS Number
52-53-9
DrugBank ID
DB00661
TTD ID
D0R0FE
VARIDT ID
DR00264
INTEDE ID
DR1681
ACDINA ID
D00726

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) TT729IR CAC1G_HUMAN Blocker [5], [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [7]
Organic cation/carnitine transporter 1 (SLC22A4) DT2EG60 S22A4_HUMAN Substrate [8]
Organic cation/carnitine transporter 2 (SLC22A5) DT3HUVD S22A5_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [14]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [15]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [16]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [18]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [14]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [19]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [20]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Verapamil
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acebutolol DM0TI4U Major Increased risk of cardiac depression by the combination of Verapamil and Acebutolol. Hypertension [BA00-BA04] [137]
Aliskiren DM1BV7W Moderate Decreased metabolism of Verapamil caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [138]
Penbutolol DM4ES8F Major Increased risk of cardiac depression by the combination of Verapamil and Penbutolol. Hypertension [BA00-BA04] [137]
Nebivolol DM7F1PA Major Increased risk of cardiac depression by the combination of Verapamil and Nebivolol. Hypertension [BA00-BA04] [137]
Levamlodipine DM92S6N Moderate Decreased metabolism of Verapamil caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [138]
Pindolol DMD2NV7 Major Increased risk of cardiac depression by the combination of Verapamil and Pindolol. Hypertension [BA00-BA04] [137]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Verapamil (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Clindamycin DM15HL8 Moderate Increased plasma concentration of Verapamil and Clindamycin due to competitive binding of plasma proteins. Acne vulgaris [ED80] [139]
Repaglinide DM5SXUV Moderate Decreased metabolism of Verapamil caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [140]
Ivosidenib DM8S6T7 Major Increased metabolism of Verapamil caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [141]
Midostaurin DMI6E0R Moderate Decreased metabolism of Verapamil caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [142]
Daunorubicin DMQUSBT Moderate Decreased clearance of Verapamil due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [143]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Verapamil caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [144]
Ivabradine DM0L594 Major Decreased metabolism of Verapamil caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [144]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Verapamil caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [145]
Cilostazol DMZMSCT Major Decreased metabolism of Verapamil caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [144]
Budesonide DMJIBAW Moderate Decreased metabolism of Verapamil caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [146]
Aminophylline DML2NIB Moderate Decreased metabolism of Verapamil caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [147]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Verapamil caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [144]
Zileuton DMVRIC2 Minor Decreased metabolism of Verapamil caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [148]
Desipramine DMT2FDC Moderate Decreased metabolism of Verapamil caused by Desipramine mediated inhibition of CYP450 enzyme. Attention deficit hyperactivity disorder [6A05] [149]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Verapamil caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [150]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Verapamil caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [151]
Ceftriaxone DMCEW64 Moderate Increased plasma concentration of Verapamil and Ceftriaxone due to competitive binding of plasma proteins. Bacterial infection [1A00-1C4Z] [139]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Verapamil caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [152]
Cariprazine DMJYDVK Moderate Decreased metabolism of Verapamil caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [153]
Pexidartinib DMS2J0Z Major Decreased metabolism of Verapamil caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [154]
Loperamide DMOJZQ9 Major Decreased clearance of Verapamil due to the transporter inhibition by Loperamide. Bowel habit change [ME05] [155]
Talazoparib DM1KS78 Major Decreased clearance of Verapamil due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [144]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Verapamil caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [156]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Verapamil caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [157]
HKI-272 DM6QOVN Major Decreased metabolism of Verapamil caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [158]
LY2835219 DM93VBZ Moderate Decreased metabolism of Verapamil caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [159]
Tucatinib DMBESUA Moderate Decreased metabolism of Verapamil caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [160]
Palbociclib DMD7L94 Moderate Decreased metabolism of Verapamil caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [144]
Alpelisib DMEXMYK Moderate Increased metabolism of Verapamil caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [161]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Verapamil caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [162]
Bosutinib DMTI8YE Major Decreased metabolism of Verapamil caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [163]
Atorvastatin DMF28YC Moderate Decreased metabolism of Verapamil caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [164]
Macitentan DMP79A1 Moderate Decreased metabolism of Verapamil caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [165]
PF-04449913 DMSB068 Moderate Decreased metabolism of Verapamil caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [166]
Indacaterol DMQJHR7 Minor Decreased metabolism of Verapamil caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [167]
Fidaxomicin DMFP6MV Minor Decreased clearance of Verapamil due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [168]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Verapamil caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [138]
Intedanib DMSTA36 Moderate Decreased metabolism of Verapamil caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [169]
Ulipristal DMBNI20 Minor Decreased metabolism of Verapamil caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [144]
Alfentanil DMVO0UB Major Decreased metabolism of Verapamil caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [170]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Verapamil caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [147]
Mifepristone DMGZQEF Moderate Decreased metabolism of Verapamil caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [171]
Pasireotide DMHM7JS Moderate Increased risk of bradycardia by the combination of Verapamil and Pasireotide. Cushing syndrome [5A70] [138]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Verapamil caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [144]
Ivacaftor DMZC1HS Major Decreased metabolism of Verapamil caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [144]
MK-8228 DMOB58Q Moderate Decreased metabolism of Verapamil caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [172]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Verapamil caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [173]
Aprepitant DM053KT Moderate Decreased metabolism of Verapamil caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [174]
Trimipramine DM1SC8M Moderate Decreased metabolism of Verapamil caused by Trimipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [149]
Vilazodone DM4LECQ Moderate Decreased metabolism of Verapamil caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [175]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Verapamil caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [176]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Verapamil and Selegiline. Depression [6A70-6A7Z] [177]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Verapamil and Isocarboxazid. Depression [6A70-6A7Z] [177]
Escitalopram DMFK9HG Minor Decreased metabolism of Verapamil caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [178]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Verapamil and Tranylcypromine. Depression [6A70-6A7Z] [177]
OPC-34712 DMHG57U Major Decreased metabolism of Verapamil caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [179]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Verapamil and Phenelzine. Depression [6A70-6A7Z] [177]
Clomipramine DMINRKW Moderate Decreased metabolism of Verapamil caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [149]
Doxepin DMPI98T Moderate Decreased metabolism of Verapamil caused by Doxepin mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [149]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Verapamil caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [180]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Verapamil caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [181]
Primidone DM0WX6I Moderate Increased metabolism of Verapamil caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [182]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Verapamil caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [183]
Stiripentol DMMSDOY Moderate Decreased metabolism of Verapamil caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [144]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Verapamil caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [184]
Ethotoin DMXWOCP Moderate Increased plasma concentrations of Verapamil and Ethotoin due to competitive inhibition of the same metabolic pathway. Epilepsy/seizure [8A61-8A6Z] [184]
Phenobarbital DMXZOCG Moderate Increased metabolism of Verapamil caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [182]
Cannabidiol DM0659E Minor Decreased metabolism of Verapamil caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [144]
Nadolol DMW6GVL Major Increased risk of cardiac depression by the combination of Verapamil and Nadolol. Essential hypertension [BA00] [137]
Dantrolene DM1D8XY Moderate Increased risk of hyperkalemia by the combination of Verapamil and Dantrolene. Fever [MG26] [185]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Verapamil caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [186]
Tazemetostat DMWP1BH Major Decreased metabolism of Verapamil caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [187]
Solifenacin DMG592Q Moderate Decreased metabolism of Verapamil caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [188]
Mirabegron DMS1GYT Minor Decreased metabolism of Verapamil caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [189]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Verapamil caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [190]
Miconazole DMPMYE8 Moderate Decreased metabolism of Verapamil caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [191]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Verapamil caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [191]
Ripretinib DM958QB Moderate Decreased metabolism of Verapamil caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [163]
Avapritinib DMK2GZX Major Decreased metabolism of Verapamil caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [144]
Metipranolol DMJMVKI Major Increased risk of cardiac depression by the combination of Verapamil and Metipranolol. Glaucoma [9C61] [192]
Levobetaxolol DMSREPX Major Increased risk of cardiac depression by the combination of Verapamil and Levobetaxolol. Glaucoma [9C61] [192]
Levobunolol DMTNFCQ Major Increased risk of cardiac depression by the combination of Verapamil and Levobunolol. Glaucoma [9C61] [192]
Colchicine DM2POTE Major Decreased metabolism of Verapamil caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [193]
Ergotamine DMKR3C5 Moderate Decreased metabolism of Verapamil caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [194]
Eplerenone DMF0NQR Major Decreased metabolism of Verapamil caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [195]
Carvedilol DMHTEAO Major Increased risk of cardiac depression by the combination of Verapamil and Carvedilol. Heart failure [BD10-BD1Z] [137]
Boceprevir DMBSHMF Moderate Decreased metabolism of Verapamil caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [196]
Simeprevir DMLUA9D Moderate Decreased clearance of Verapamil due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [197]
Telaprevir DMMRV29 Moderate Decreased metabolism of Verapamil caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [196]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Verapamil caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [163]
Rifampin DMA8J1G Moderate Increased metabolism of Verapamil caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [198]
Rifapentine DMCHV4I Moderate Increased metabolism of Verapamil caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [199]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Verapamil and Procarbazine. Hodgkin lymphoma [2B30] [177]
MK-1439 DM215WE Minor Decreased metabolism of Verapamil caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [200]
Delavirdine DM3NF5G Moderate Decreased metabolism of Verapamil caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [201]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Verapamil caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [202]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Verapamil caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [203]
Tipranavir DM8HJX6 Moderate Accelerated clearance of Verapamil due to the transporter induction by Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [204]
Dolutegravir DMCZGRE Minor Decreased metabolism of Verapamil caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [205]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Verapamil caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [163]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Verapamil caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [202]
Darunavir DMN3GCH Moderate Decreased metabolism of Verapamil caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [206]
Maraviroc DMTL94F Moderate Decreased clearance of Verapamil due to the transporter inhibition by Maraviroc. Human immunodeficiency virus disease [1C60-1C62] [207]
BMS-201038 DMQTAGO Major Decreased metabolism of Verapamil caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [163]
Conivaptan DM1V329 Moderate Decreased metabolism of Verapamil caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [208]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Verapamil caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [209]
Retapamulin DM9JXB7 Minor Decreased metabolism of Verapamil caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [210]
Berotralstat DMWA2DZ Major Decreased clearance of Verapamil due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [211]
Suvorexant DM0E6S3 Major Decreased metabolism of Verapamil caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [212]
Amobarbital DM0GQ8N Moderate Increased metabolism of Verapamil caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [182]
Ramelteon DM7IW9J Moderate Decreased metabolism of Verapamil caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [213]
Triazolam DMETYK5 Moderate Decreased metabolism of Verapamil caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [214]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Verapamil and Propiomazine. Insomnia [7A00-7A0Z] [215]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Verapamil caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [216]
ITI-007 DMUQ1DO Major Decreased metabolism of Verapamil caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [217]
Naloxegol DML0B41 Major Decreased metabolism of Verapamil caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [144]
Pemigatinib DM819JF Major Decreased metabolism of Verapamil caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [144]
Brigatinib DM7W94S Major Decreased metabolism of Verapamil caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [163]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Verapamil caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [218]
PF-06463922 DMKM7EW Moderate Increased metabolism of Verapamil caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [219]
Osimertinib DMRJLAT Moderate Decreased metabolism of Verapamil caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [220]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Verapamil caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [221]
Capmatinib DMYCXKL Moderate Decreased clearance of Verapamil due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [222]
Selpercatinib DMZR15V Major Decreased metabolism of Verapamil caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [144]
Halofantrine DMOMK1V Major Decreased metabolism of Verapamil caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [223]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Verapamil caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [163]
Idelalisib DM602WT Moderate Decreased metabolism of Verapamil caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [224]
GDC-0199 DMH0QKA Major Decreased metabolism of Verapamil caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [163]
IPI-145 DMWA24P Moderate Decreased metabolism of Verapamil caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [225]
Acalabrutinib DM7GCVW Major Decreased metabolism of Verapamil caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [226]
Ibrutinib DMHZCPO Major Decreased metabolism of Verapamil caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [227]
Arry-162 DM1P6FR Moderate Decreased clearance of Verapamil due to the transporter inhibition by Arry-162. Melanoma [2C30] [163]
Vemurafenib DM62UG5 Minor Decreased metabolism of Verapamil caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [163]
Selumetinib DMC7W6R Major Decreased metabolism of Verapamil caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [228]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Verapamil caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [144]
Ubrogepant DM749I3 Moderate Decreased metabolism of Verapamil caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [229]
Almogran DM7I64Z Minor Decreased metabolism of Verapamil caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [230]
Rimegepant DMHOAUG Moderate Decreased metabolism of Verapamil caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [231]
Exjade DMHPRWG Moderate Decreased metabolism of Verapamil caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [232]
Flibanserin DM70DTN Major Decreased metabolism of Verapamil caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [233]
Midazolam DMXOELT Moderate Decreased metabolism of Verapamil caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [214]
Panobinostat DM58WKG Moderate Decreased metabolism of Verapamil caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [234]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Verapamil and Thalidomide. Multiple myeloma [2A83] [163]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Verapamil and Siponimod. Multiple sclerosis [8A40] [163]
Fingolimod DM5JVAN Major Increased risk of bradycardia by the combination of Verapamil and Fingolimod. Multiple sclerosis [8A40] [235]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Verapamil and Ozanimod. Multiple sclerosis [8A40] [236]
Romidepsin DMT5GNL Moderate Decreased clearance of Verapamil due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [237]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Verapamil caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [144]
Nilotinib DM7HXWT Moderate Decreased metabolism of Verapamil caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [238]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Verapamil caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [144]
Modafinil DMYILBE Moderate Increased metabolism of Verapamil caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [163]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Verapamil and Promethazine. Nausea/vomiting [MD90] [215]
Entrectinib DMMPTLH Major Decreased metabolism of Verapamil caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [163]
Sibutramine DMFJTDI Minor Decreased metabolism of Verapamil caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [239]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Verapamil caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [240]
MK-4827 DMLYGH4 Moderate Decreased clearance of Verapamil due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [241]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Verapamil caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [242]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Verapamil and Safinamide. Parkinsonism [8A00] [177]
Istradefylline DM20VSK Moderate Decreased metabolism of Verapamil caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [243]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Verapamil and Rasagiline. Parkinsonism [8A00] [177]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Verapamil caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [244]
Abametapir DM2RX0I Moderate Decreased metabolism of Verapamil caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [245]
Lefamulin DME6G97 Major Decreased metabolism of Verapamil caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [246]
Ergonovine DM0VEC1 Moderate Decreased metabolism of Verapamil caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [247]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Verapamil caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [248]
Enzalutamide DMGL19D Moderate Decreased metabolism of Verapamil caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [249]
Relugolix DMK7IWL Major Decreased clearance of Verapamil due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [250]
Darolutamide DMV7YFT Minor Decreased metabolism of Verapamil caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [251]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Verapamil caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [252]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Verapamil caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [253]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Verapamil and Levomepromazine. Psychotic disorder [6A20-6A25] [215]
Riociguat DMXBLMP Moderate Decreased metabolism of Verapamil caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [163]
Everolimus DM8X2EH Major Decreased metabolism of Verapamil caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [254]
Axitinib DMGVH6N Moderate Decreased metabolism of Verapamil caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [144]
Temsirolimus DMS104F Moderate Decreased metabolism of Verapamil caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [255]
Upadacitinib DM32B5U Moderate Decreased metabolism of Verapamil caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [256]
Tofacitinib DMBS370 Moderate Decreased metabolism of Verapamil caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [163]
Quetiapine DM1N62C Moderate Decreased metabolism of Verapamil caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [257]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Verapamil and Mesoridazine. Schizophrenia [6A20] [215]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Verapamil and Thioridazine. Schizophrenia [6A20] [215]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Verapamil and Iloperidone. Schizophrenia [6A20] [215]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Verapamil and Paliperidone. Schizophrenia [6A20] [215]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Verapamil and Perphenazine. Schizophrenia [6A20] [215]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Verapamil and Molindone. Schizophrenia [6A20] [215]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Verapamil and Thiothixene. Schizophrenia [6A20] [215]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Verapamil and Trifluoperazine. Schizophrenia [6A20] [215]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Verapamil and Risperidone. Schizophrenia [6A20] [215]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Verapamil and Amisulpride. Schizophrenia [6A20] [144]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Verapamil and Asenapine. Schizophrenia [6A20] [215]
Fentanyl DM8WAHT Major Decreased metabolism of Verapamil caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [163]
Avanafil DM75CXN Major Decreased metabolism of Verapamil caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [258]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Verapamil caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [259]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Verapamil caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [260]
LDE225 DMM9F25 Major Decreased metabolism of Verapamil caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [261]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Verapamil caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [144]
Larotrectinib DM26CQR Moderate Decreased clearance of Verapamil due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [163]
Docetaxel DMDI269 Major Decreased metabolism of Verapamil caused by Docetaxel mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [262]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Verapamil caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [144]
Armodafinil DMGB035 Moderate Increased metabolism of Verapamil caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [163]
LEE011 DMMX75K Moderate Decreased metabolism of Verapamil caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [163]
Taxol DMUOT9V Moderate Decreased metabolism of Verapamil caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [263]
Doxorubicin DMVP5YE Moderate Interference of cell/tissue uptake of Verapamil by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [264]
Pitolisant DM8RFNJ Moderate Increased metabolism of Verapamil caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [144]
Pomalidomide DMTGBAX Moderate Decreased clearance of Verapamil due to the transporter inhibition by Pomalidomide. Systemic sclerosis [4A42] [163]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Verapamil caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [265]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Verapamil due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [266]
Apixaban DM89JLN Moderate Decreased metabolism of Verapamil caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [144]
Brilinta DMBR01X Moderate Decreased metabolism of Verapamil caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [144]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Verapamil caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [267]
Tizanidine DMR2IQ4 Major Decreased metabolism of Verapamil caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [268]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Verapamil caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [269]
Saxagliptin DMGXENV Moderate Decreased metabolism of Verapamil caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [144]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Verapamil and Methdilazine. Vasomotor/allergic rhinitis [CA08] [215]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Verapamil and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [270]
Fluticasone DMGCSVF Moderate Decreased metabolism of Verapamil caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [163]
Amiodarone DMUTEX3 Major Increased risk of bradycardia by the combination of Verapamil and Amiodarone. Ventricular tachyarrhythmia [BC71] [271]
⏷ Show the Full List of 216 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
D&C red no. 33 E00261 19116 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
methylparaben E00149 7456 Antimicrobial preservative
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium sulfate anhydrous E00303 24497 Desiccant; Diluent
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dibutyl sebacate E00160 7986 Plasticizing agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 40 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Verapamil 200 mg capsule 200 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 100 mg capsule 100 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 300 mg capsule 300 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 240 mg capsule 240 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 120 mg capsule 120 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 180 mg capsule 180 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 360 mg capsule 360 mg 24 HR Extended Release Oral Capsule Oral
Verapamil 120 mg capsule 120 mg 24 HR Extended Release Capsule Oral
Verapamil 180 mg tablet 180 mg 24 HR Extended Release Oral Tablet Oral
Verapamil 240 mg tablet 240 mg 24 HR Extended Release Oral Tablet Oral
Verapamil 120 mg tablet 120 mg Extended Release Oral Tablet Oral
Verapamil 180 mg tablet 180 mg Extended Release Oral Tablet Oral
Verapamil 240 mg tablet 240 mg Extended Release Oral Tablet Oral
Verapamil 40 mg tablet 40 mg Oral Tablet Oral
Verapamil 120 mg tablet 120 mg Oral Tablet Oral
Verapamil 80 mg tablet 80 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2406).
2 Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol. 2008 Feb;6(2):e26.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
6 Combination therapy and target organ protection in hypertension and diabetes mellitus. Am J Hypertens. 1997 Sep;10(9 Pt 2):198S-201S.
7 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
8 Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
9 Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
10 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
11 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12 Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
15 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
16 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
17 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
18 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
19 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
20 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
21 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
22 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
23 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
24 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
25 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
26 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
27 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
28 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
29 Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
30 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
31 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
32 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
33 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
34 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
35 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
36 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
37 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
38 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
39 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
40 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
41 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
42 Drug Interactions Flockhart Table
43 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
44 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
45 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
46 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
47 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
48 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
49 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
50 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
51 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
52 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
53 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
54 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
55 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
56 Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
57 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
58 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
59 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
60 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
61 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
62 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
63 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
64 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
65 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
66 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
67 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
68 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
69 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
70 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
71 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
72 Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
73 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
74 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
75 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
76 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
77 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
78 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
79 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
80 In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
81 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
82 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
83 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
84 Drugs that may have potential CYP2B6 interactions.
85 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
86 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
87 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
88 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
89 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
90 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
91 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
92 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
93 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
94 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
95 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
96 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
97 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
98 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
99 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
100 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
101 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
102 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
103 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
104 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
105 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
106 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
107 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
108 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
109 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
110 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
111 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
112 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
113 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
114 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
115 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
116 Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
117 Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
118 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
119 Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
120 Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
121 Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
122 Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
123 Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
124 Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
125 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
126 Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
127 Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
128 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics. 2007 Sep;17(9):773-82.
129 Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
130 Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
131 Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
132 Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
133 Pfizer. Product Development Pipeline. March 31 2009.
134 The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
135 Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
136 Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
137 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
138 Canadian Pharmacists Association.
139 Kishore K, Raina A, Misra V, Jonas E "Acute verapamil toxicity in a patient with chronic toxicity: possible interaction with ceftriaxone and clindamycin." Ann Pharmacother 27 (1993): 877-80. [PMID: 8364267]
140 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
141 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
142 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
143 Multum Information Services, Inc. Expert Review Panel.
144 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
145 Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
146 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
147 Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
148 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
149 Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
150 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
151 Goldschmidt N, Azaz-Livshits T, Gotsman, Nir-Paz R, Ben-Yehuda A, Muszkat M "Compound cardiac toxicity of oral erythromycin and verapamil." Ann Pharmacother 35 (2001): 1396-9. [PMID: 11724091]
152 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
153 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
154 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
155 Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013]
156 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
157 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
158 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
159 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
160 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
161 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
162 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
163 Cerner Multum, Inc. "Australian Product Information.".
164 Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
165 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
166 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
167 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
168 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
169 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
170 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
171 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
172 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
173 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
174 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
175 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
176 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
177 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
178 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
179 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
180 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
181 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
182 Rutledge DR, Pieper JA, Mirvis DM "Effects of chronic phenobarbital on verapamil dispostion in humans." J Pharmacol Exp Ther 246 (1988): 7-13. [PMID: 3392664]
183 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
184 Hedman A, Angelin B, Arvidsson A, et al "Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans." Clin Pharmacol Ther 49 (1991): 256-62. [PMID: 2007320]
185 Rubin AS, Zablocki AD "Hyperkalemia, verapamil, and dantrolene." Anesthesiology 66 (1987): 246-9. [PMID: 3813090]
186 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
187 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
188 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
189 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
190 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
191 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
192 Packer M "Combined beta-adrenergic and calcium-entry blockage in angina pectoris." N Engl J Med 320 (1989): 709-18. [PMID: 2564164]
193 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
194 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
195 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
196 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
197 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
198 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
199 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
200 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
201 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
202 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
203 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
204 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
205 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
206 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
207 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
208 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
209 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
210 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
211 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
212 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
213 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
214 Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ "Dose of midazolam should be reduced during diltiazem and verapamil treatments." Br J Clin Pharmacol 37 (1994): 221-5. [PMID: 8198928]
215 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
216 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
217 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
218 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
219 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
220 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
221 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
222 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
223 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
224 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
225 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
226 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
227 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
228 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
229 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
230 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
231 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
232 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
233 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
234 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
235 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
236 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
237 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
238 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
239 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
240 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
241 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
242 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
243 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
244 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
245 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
246 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
247 Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
248 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
249 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
250 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
251 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
252 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
253 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
254 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
255 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
256 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
257 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
258 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
259 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
260 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
261 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
262 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
263 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
264 Li W, Zhang H, Assaraf YG, et al. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.?Drug Resist Updat. 2016;27:14-29. [PMID: 27449595]
265 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
266 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
267 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
268 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
269 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
270 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
271 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]